Biography

Jeffrey (Jeff) W. Sherman, MD, FACP, has more than 30 years of experience in the biopharmaceutical industry.  He was most recently the Chief Medical Officer and Executive Vice President at Horizon Therapeutics until its acquisition by Amgen.  Dr. Sherman also served on the Board of Directors of Strongbridge prior to its acquisition by Xeris Pharmaceuticals, Inc in 2021. Additionally, Dr. Sherman served previously on the Board of Directors of the Biotechnology Innovation Organization (BIO), Larimar Therapeutics and of Sorriso Pharmaceuticals, Inc. He is a member of a number of professional societies, a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine, and on the Board of Advisors of the Center for Information and Study on Clinical Research Participation. He previously held positions at pharmaceutical companies such as IDM Pharma, Inc., Takeda Global Research and Development, NeoPharm Inc., G.D. Searle, LLC/Pharmacia Corporation, and BristolMyers Squibb, and is a past board chair of the Drug Information Association.

Dr. Sherman received a B.A. in Biology from Lake Forest College and earned his M.D. from the Rosalind Franklin University of Medicine and Science/The Chicago Medical School. Dr. Sherman completed internship and residency programs at Northwestern University Feinberg School of Medicine, where he currently serves as an adjunct assistant professor, and a fellowship program at the University of California, San Francisco.

Committee Roles:
Member of the Compensation Committee
Member of the Nominating Governance Committee